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People with disabilities who have functional mobility limitations often rely on mobility assistive 
equipment (MAE) to perform Mobility Related Activities of Daily Living (MRADLs). If an 
individual is not appropriately evaluated for Mobility Assistive Equipment to address current and 
prepare for future needs, negative outcomes are to be expected. The purpose of this study was to 
investigate differences between if an Assistive Technology Professional (ATP) was involved in 
the provision of MAE or if there was no ATP. The variables compared were based on 
demographics, current primary MAE, and baseline FMA scores. The data being analyzed was 
received through a pre-existing registry, with a population size of 2085 whereby 1123 met the 
inclusion criteria. If an ATP was involved, the individual using the MAE was more likely to have 
lived with their medical condition longer and use the MAE longer. The data shows that elderly 
females were more likely to not have an ATP, however a post hoc analysis determined that this 
result was more related to diagnosis than ATP involvement. Individuals who had an ATP were 
being provided with better quality MAE, being Group 3 power wheelchairs and ultra-lightweight 
manual wheelchairs compared to other wheelchairs, cane, crutches, or walkers if there was not 
an ATP involved. Baseline FMA scores suggest that having an ATP involved in the provision of 
MAE results in higher satisfaction scores than not having an ATP. Overall, this study provides 
evidence that an ATP has a positive impact on MAE provision by providing better quality MAE 
that is more durable and leads to higher self-reported satisfaction ratings.  
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1.0  INTRODUCTION 
Over a billion people in the world have some form of disability. Between 100 million and 
190 million adults have difficulties performing activities of daily living such as, dressing, 
bathing, and eating. With the rates of disabilities increasing due to an aging population, increase 
in chronic health conditions and amongst other reasons, more people are relying on mobility 
assistive equipment (MAE) (World Health Organization, 2018). MAE includes but are not 
limited to canes, crutches, walkers, wheelchairs (power and manual), and scooters. Medicare is 
the largest funding source for mobility MAEs in the United States and will typically replace a 
MAE once every five years (Medicare Rights Center, 2019). Thus, individuals who are receiving 
funding through Medicare must receive MAE that meets their needs and durable enough to last 
the five years. If individuals are not provided with the best MAE that fits their needs, a well-
documented issue is abandoning their MAE (Scherer & Federici, 2015). MAE abandonment 
results in dissatisfaction, frustration, and wasting their financial resources (Batavia & Hammer, 
1990). The most frequently abandoned mobility MAE are wheelchairs, followed by canes and 
walkers. Four predictive variables were identified that could result in abandonment are: change 
in the needs of the user, ease of obtaining the MAE from the supplier, meeting the user’s 
expectations, and whether the user’s opinion was considered in the selection process (Phillips & 
Zhao, 1993). 
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The Rehabilitation Engineering and Assistive Technology Society of North America 
(RESNA) has developed an Assistive Technology Professional (ATP) certification that requires 
candidates to meet educational and work experience requirements that covers all major areas of 
assistive technology (AT). The ATP certification recognizes an individual’s competence in 
analyzing the needs of people with disabilities, help with the selection of appropriate AT and 
providing the training in the use of the selected MAEs (RESNA, 2019). Health care professionals 
that primarily practice within the AT field generally agree that a team approach is optimal. 
Although the role of an ATP involvement is expected to be of high value, little research has been 
examined to show the relationship between ATP involvement and service delivery outcomes. 
(Jette et al., 2017).  
The purpose of this study was to examine the differences in demographics, type of MAE 
provided, and Functional Mobility Assessment (FMA) scores between whether an ATP was 
involved or not in the provision of MAE. Three hypotheses that were investigated are as follows: 
- Null Hypothesis 1: There will not be a statistically significant difference regarding 
age of person, gender, diagnosis, age of current primary MAE, and number of years 
since onset of diagnosis between groups with ATP involvement or no ATP 
involvement during mobility assistive equipment provision. 
- Null Hypothesis 2: There will not be a statistically significant difference in current 
primary MAE between groups with ATP involvement or no ATP involvement during 
mobility assistive equipment provision. 
- Null Hypothesis 3: There will not be a statistically significant difference in FMA 
scores between groups with ATP involvement or no ATP involvement during 
mobility assistive equipment provision. 
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1.1 BACKGROUND 
People with disabilities (PwD) are often underestimated on what they are capable of. 
Disability is often viewed as a limiting factor, but their environment plays a major role in 
determining what they can do and be (Lid & Solvang, 2015). Although there is a wide variety of 
mobility-related technologies, there were about 3.6 million wheelchair users and 11.6 million 
people using a cane, crutch or walker in the United States in 2010. (US Census Bureau, 2012). 
This number is expected to grow due to the aging baby boomers and their increasing longevity. 
Although access to wheeled-mobility is vital, the proper process of service and delivery is where 
the persons functional abilities can be maximized. Improper service delivery can limit the 
persons functional abilities with self-care, participation in the community and employment. 
These complications can lead to secondary injuries, dependability on others and abandonment.  
MAE such as scooters, manual wheelchairs and power wheelchairs are easily accessible 
in the market. Like purchasing a new vehicle, it is important for PwD to have objective 
information regarding the safety and durability of these MAE. The American National Standards 
Institute (ANSI) and Rehabilitation Engineering and Assistive Technology Society of North 
America (RESNA) have developed standardized testing to provide objective measurements. 
Although these standards have been established, the Food and Drug Administration (FDA) does 
not require wheelchair manufactures to meet these standards. The amount of manual and power 
wheelchairs that have not passed the ANSI/RESNA standards have been well documented 
(Rentschler et al., 2004; Souza et al., 2013; Kwarciak et al., 2005). These MAEs that have not 
pass ANSI/RESNA standards can become consequential for the users such as: injury, being 
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stranded, missing medical appointments, and inability to attend school/work (Hogaboom et al., 
2018; Worobey et al., 2012).  
RESNA has developed a Wheelchair Service Provision Guide to identify the essential 
steps in the provision of a wheelchair (Arledge et al., 2011). The components included in this 
wheelchair service delivery model include: Referral, Assessment, Equipment Recommendation 
and Selection, Funding and Procurement, Product Preparation, Fitting, Training and Delivery, 
Follow-up Maintenance and Repair, and Outcome Measurement. The guide further recommends 
that people who will be using a wheelchair and/or seating system for at least six months or on a 
permanent basis should be referred to a therapist (physical or occupational) and supplier who are 
both qualified, skilled and experienced in seating and mobility. The assessment component 
consists of three categories structured by the International Classification of Functioning, 
Disability, and Health (ICF): Body Structures and Functions; Activities and Participation; and 
Environment and Current Technology. Following the assessment, the client should be properly 
fitted and trained on the MAE being prescribed (Arledge et al., 2011).  
In addition to the Wheelchair Service and Provision Guide, RESNA has also established 
“Standards of Practice” for ATP’s. The Standards of Practice are 22 essential concepts and rules 
to consider promoting the highest ethical standards among individuals who evaluate, identify 
needs, recommend or providing assistive technology (RESNA, 2016) (see Appendix A). By 
following these Standards of Practice, ATP’s can achieve the desired level of performance to 
help prevent major issues related to MAE, such as abandonment. Several factors that have been 
predictors of MAE abandonment are: change in needs, MAE performance, and client opinion not 
being considered in the selection (Phillips & Zhao, 1993; Reimer-Reiss & Wacker, 2000). 
Although the Standards of Practice address all the predictive factors of MAE abandonment, little 
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research has examined the relationship between ATP involvement and service delivery outcomes 
(Jette et al., 2017). 
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2.0  METHODS 
2.1 STUDY DESIGN 
 
The data for this study was received from the Functional Mobility Assessment/Uniform 
Dataset (FMA/UDS) Registry. Data from the FMA/UDS Registry is collected through an exempt 
IRB at the University of Pittsburgh and by a vetted Collaborative Corporate Research Agreement 
with the Van G. Miller Group, Inc. and its subsidiary U.S. Rehab (VGM/US Rehab). U.S. Rehab 
suppliers collaborate with clinicians to administer the FMA/UDS to people at the time of initial 
evaluation for a new mobility intervention and at period set times following provision of new 
MAE device. Specific variables such as ATP involvement, age, gender, year of onset, age of 
MAE, primary diagnosis, current primary MAE, and baseline FMA scores were exported from 
the FMA/UDS Registry at baseline to review for further analyses (Schmeler et al., 2019) At the 
time of this study, the registry consisted of 2085 baseline scores of individuals collected between 
7/7/2015 – 10/8/2018 across 166 individual providers representing 40 States. 
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2.2 PARTICIPANTS 
Of the 2085 baseline cases in the FMA/UDS Registry, 1123 cases indicated there was or 
was not an ATP involved (versus unknown) in the provision of their MAE and had a complete 
FMA/UDS dataset therefore met the inclusion criteria for this study. There were 523 complete 
datasets that indicated there was an ATP involved in the provision of their MAE and 600 cases 
that reported there was no ATP involved (See Table 1). 
Of those 1123 cases, the following variables were included in the analyses: 
- Year of Birth 
- Gender 
- Age of their current MAE at baseline 
- Year of Diagnosis Onset 
- Primary Diagnosis 
- Current type Primary MAE at baseline 
- Baseline FMA score 
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Table 1 Demographics and Results Descriptive   
 ATP No ATP Total 
Demographics n = 523 n = 600 N = 1123 
Age, M±SD 56.50±17.58 65.01±15.52 61.05±17.04 
     Range 19 - 106 19 – 99 
 
19 - 106 
Gender, n(%)    
     Female 249 (47.6%) 336 (56.0%) 585 (52.1%) 
     Male 274 (52.4%) 264 (44%) 
 
538 (47.9%) 
Age of MAE, M±SD 5.39±2.20 4.29±2.94 4.80±2.68 
Years Since Onset, M±SD 24.52 ±18.14 15.66 ±16.55 
 
19.79 ±17.85 
Diagnosis, n(%)    
     Osteoarthritis 12 (2.3%) 48 (8.0%) 60 (5.30%) 
     Amyotrophic Lateral Sclerosis/ 
     Primary Lateral Sclerosis 
6 (1.1%) 28 (4.7%) 34 (3.00%) 
     Rheumatoid Arthritis 4 (.8%) 16 (2.7%) 20 (1.85) 
     Stroke/CVA 66 (12.6%) 112 (18.7%) 178 (15.95) 
     Multiple Sclerosis 56 (10.7%) 59 (9.8%) 115 (10.2%) 
     Amputation 17 (3.3%) 38 (6.3%) 55 (4.95) 
     Cardiopulmonary Disease 4 (.8%) 26 (4.3%) 30 (2.7%) 
     Cerebral Palsy 70 (13.4%) 26 (4.3%) 96 (8.5%) 
     Morbid Obesity 15 (2.9%) 32 (5.3%) 47 (4.2%) 
     SCI (Paraplegia) 63 (12.0%) 24 (4.0%) 87 (7.7%) 
     SCI (Tetraplegia/Quadriplegia) 51 (9.8%) 16 (2.7%) 67 (6.0%) 
     Parkinson Disease 5 (1.0%) 36 (6.0%) 41 (3.7%) 
     Traumatic Brain Injury (TBI) 10 (1.9%) 9 (1.5%) 19 (1.7%) 
     Post-Polio Syndrome 20 (3.8%) 11 (1.8%) 31 (2.8%) 
     Muscular Dystrophy 18 (3.4%) 5 (.8%) 23 (2.0%) 
     Spinal Stenosis 6 (1.1%) 10 (1.7%) 16 (1.4%) 
     Spina Bifida 27 (5.2%) 7 (1.2%) 34 (3.0%) 
     Cerebellar Degeneration,    
     Arthrogryposis, Spinocerebellar 
     Disease, Osteogenesis Imperfecta, Spinal    
     Muscular Atrophy (SMA) 
10 (1.9%) 9 (1.5%) 19 (1.7%) 
     Other Neuromuscular or Congenital     
     Disease (Not Listed Above) 
63 (12.0%) 88 (14.7%) 151 (13.4%) 
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Table 1 (continued) 
 ATP No ATP Total 
Current Primary MAE, n(%) 31 (5.9%) 154 (25.7%) 185 (16.5%) 
     Cane, Crutches, Walker 41 (7.8%) 262 (43.7%) 303 (27.0%) 
     Other Wheelchairs* 100 (19.1%) 18 (3.0%) 118 (10.5%) 
     Ultra-Lightweight Manual Wheelchair 11 (2.1%) 3 (.5%) 14 (1.2%) 
     Tilt-in-Space Wheelchair 9 (1.7%) 26 (4.3%) 35 (3.1%) 
     POV/Scooter 4 (.8%) 10 (1.7%) 14 (1.2%) 
     Group 1 Power Wheelchair 89 (17.0%) 110 (18.3%) 199 (17.7%) 
     Group 2 Power Wheelchair 233 (44.6%) 17 (2.8%) 250 (22.3%) 
     Group 3 Power Wheelchair 5 (1.0%) 0 5 (.4%) 
     Group 4 Power Wheelchair    
FMA Score, M±SD 37.31±15.60 25.69±12.67 31.10±15.25 
     Range 0 - 60 0 - 60 0 - 60 
*Other Wheelchairs includes – Standard Manual Wheelchair, Lightweight Manual Wheelchair, 
Bariatric Wheelchair, and Transport Wheelchair (attendant operated) 
 
 
2.3 INSTRUMENTATION 
The FMA/UDS was the only instrument included in this study. The FMA is a self-
reported questionnaire that measures an individual’s satisfaction in performing Mobility Related 
Activities of Daily Living (MRADLs). The questionnaire consists of ten statements that the 
individual can rate on a scale of 1-6. The scaling is measured as follows: 1-completely disagree, 
2-mostly disagree, 3-slightly disagree, 4-slight agree, 5-mostly agree, 6-completely agree 
(Kumar et al, 2013). The FMA/UDS tool is typically administered by a trained VGM/US Rehab 
provider or clinician at baseline when a PwD is being evaluated for a new MAE and at periodic 
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times following provision of the new MAE intervention (Schmeler et at., 2019). For the purpose 
of this study, only the baseline FMA score were investigated.  
2.4 PROCEDURE 
Baseline data was collected through the FMA/UDS Registry. All cases were previously 
given a unique identification number to protect the identity of each individual. Variables that 
were not investigated were eliminated from the dataset. Age was determined by subtracting the 
year of birth by the year this study was done, 2018. Age of the MAE was treated as ordinal data. 
The category “1 Year or less” was treated as 1 year old and the category “10 Years or more” was 
treated as 11 years old. Certain MAEs were grouped together under the Current Primary MAE 
variable. Standard Manual Wheelchair, Lightweight Manual Wheelchair, and Bariatric 
Wheelchair and Transport Wheelchair (attendant operated) were all in grouped in the “Other 
Wheelchair” category. The remaining MAE were treated as individual categories. One group was 
created in the Diagnosis variable. Cerebellar Degeneration, arthrogryposis, osteogenesis 
imperfect, and spinal muscular atrophy (SMA) were grouped under the same category. All 
remaining diagnoses were treated as individual categories. The remaining cases were divided 
into two groups: ATP involvement or no ATP involvement. 
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2.5 DATA ANALYSIS 
IBM SPSS Statistics Version 25.0 was used to conduct all the statistical tests. All tests 
used an alpha level of 0.05. Each variable was investigated and compared by two groups, ATP vs 
no ATP. Continuous data was tested for normality and homogeneity of variance through the 
Shapiro-Wilk and Levene’s Test, respectively. A 2-sample T-test was performed comparing each 
group. The variables being assessed by the 2-sample T-test was age of person, age of MAE, 
number of years since onset of medical condition and FMA score. A Crosstabulation and Chi-
Square test was used to compare gender, diagnosis and primary current MAE.  
2.6 RESULTS 
The total population between both groups was 1123 (ATP = 523; No ATP = 600). In all 
cases, the Shapiro-Wilk test determined that the distribution of each group is not normally 
distributed. Non-normal distribution is a violation of the 2-sample T-test, however the Central 
Limit Theorem (CLT) states that if n > 30, the means of the distribution is approximately normal 
(Kawk & Kim, 2017). Levene’s test of homogeneity of variance were statistically significant in 
all cases. With this result, a t-statistic not assuming equal variances was computed. All 
Crosstabulation and Chi Square tests had less than 20% of cells with an expected count less than 
5, thus the Chi Square test was not violated. 
The average age of the population in the ATP involvement group (M=56.50, SD=17.58) 
was younger than the population who did not have an ATP (M=65.01, SD=15.52) and the 
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difference in means was statistically significant between groups t(1049) = -8.55, p =0.000 (See 
Figure 1). A significant amount of females did not have an ATP (n=336) compared to those with 
an ATP (n=249) causing an unequal distribution between the two groups X2(1)=7.88, p=0.005 
(See Figure 2). Diagnosis was not equally distributed between the two groups X2(18)=187.24, 
p=0.000. The most prevalent diagnoses in the ATP involvement group was cerebral palsy 
(13.4%) and stroke/CVA (12.6%). The most prevalent diagnoses in the no ATP group was 
stroke/CVA (18.7%) and other neurological or congenital disease (14.7%) (See Figure 3). PwD 
with an ATP used their MAE longer (M=5.39, SD=2.20) than PwD who did not have an ATP 
(M=4.29, SD=2.94) and the difference was statistically significant t(1096) = 7.21, p=0.000 (See 
Figure 4). The population in the ATP involvement group lived with their medical condition 
longer (M=24.52, SD=18.14) than the population without an ATP (M=15.66, SD=16.55). The 
difference in number of years since onset was statistically significant t(1065) = 8.51, p = 0.001 
(See Figure 5). 
Current primary MAE was not equally distributed between the two groups X2(8)=506.29, 
p=0.000. The most common MAE in the ATP involvement group are Group 3 power wheelchair 
and ultra-lightweight manual wheelchair. The most common MAEs in the no ATP group are 
other wheelchairs and cane, crutches, walkers (See Figure 6). PwD reported higher FMA scores 
(M=37.31, SD=15.60) compared to the no ATP group (M=25.69, SD=12.67) and the results 
were statistically significant t(1005) = 13.57, p=0.000 (See Figure 7).   
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Figure 1 Age Distribution 
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Figure 2 Gender Comparison Between Groups 
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Figure 3 Diagnosis Comparison Between Groups 
 
 
16 
 
 
9
0
05
001
051
002
4.2 8.4 2.7 6.
A
yc
n
e
u
q
er
F
EAM fO eg
N
PTA
DEVLOVNI
seY
o
 
Figure 4 Age of MAE Distribution 
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Figure 5 Years Since Onset Distribution  
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Figure 6 Current MAE Comparison  
Other Wheelchairs includes – Standard Manual Wheelchair, Lightweight Manual Wheelchair, Bariatric Wheelchair, and 
Transport Wheelchair (attendant operated) 
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Figure 7 FMA Distribution 
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3.0  DISCUSSION 
3.1 NULL HYPOTHESIS 1 
All analyses showed statistical significance when comparing the two groups; thus, the 
null hypothesis is rejected. The data shows that the average age of a person that did not have an 
ATP when receiving their MAE is statistically higher than if someone did have an ATP. This 
result means that the older a person is, that person is less likely to not have an ATP when being 
assessed for a MAE. Gender distribution between the two group were found to be statistically 
significant. This is likely from the disparity in the number of females in each group. This result 
implies that females who need a MAE are less likely to be evaluated by an ATP. The distribution 
of diagnosis was statistically different between the two groups. These results show that the 
diagnoses comprising the two groups are different, however the top three most common 
diagnoses in both groups qualify for a group 3 power wheelchair. The average age of current 
primary MAE was statistically significant when comparing the two groups. The data shows that 
if a person has an ATP, they are likely to keep the MAE one year longer than if there is no ATP 
involved. This is significant because Medicare and other funding sources typically pay to replace 
MAE after it has reached a 5-year lifecycle. There is a statistically significant difference in 
number of years since onset between the two groups. The data shows that the longer a person has 
lived with their disability, the more likely they will have been involved with an ATP.  
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 Post hoc analyses were conducted in order to confirm a statistically significant difference 
in age and gender based on the most prevalent diagnoses between both groups. There is a 
statistically significant difference in age of person based on the top five most prevalent diagnosis 
in the ATP involvement group (M=57.41, SD=17.44) and no ATP group (M=66.18, SD=14.45) 
t(617) = -7.10, p = 0.000. Three of the most prevalent diagnoses in each group were similar, 
stroke/CVA, multiple sclerosis and other neurological/congenital disease. The other two of the 
most prevalent diagnoses in the ATP group had a younger population, Cerebral Palsy (M=41.61, 
SD=16.31) and SCI (Paraplegia) (M=54.51, SD=14.42) whereas the no ATP had two older 
populations, Osteoarthritis (M=74.50, SD=12.46) and Amputation (M=61.87, SD=13.63) (See 
Table 2). 
 
Table 2 Age Comparison Based on Most Prevalent Diagnoses** 
  
ATP1 
  
  No ATP2 
   
95% CI 
 M SD  M SD t M 
Difference 
Lower Upper 
Age 57.41 17.44  66.18 14.45 -7.02* -8.76 -11.20  -6.33 
* p < 0.05, ** includes Stroke/CVA, Multiple Sclerosis, and Other Neurological/Congenital 
Disease. 1includes Cerebral Palsy and SCI (Paraplegia), 2includes Osteoarthritis and 
Amputation 
 
 
 When comparing gender distribution based on the three most prevalent and same diagnoses 
found in each group (stroke, other neurological/congenital disease and multiple sclerosis), gender 
was evenly distributed between both groups X2(1)=0.059, p=0.808  (See Table 3). These results 
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imply that age and gender may not be a determining factor on whether a PwD has an ATP or not 
because the average ages and gender in both group were influenced based on a difference in 
diagnoses.  
 
 
Table 3 Gender Comparison Based on Most Prevalent and Common Diagnoses** 
 
 ATP  
 Yes No X2 
Females, n(%) 108 (41.1%) 155 (58.9%) 0.059 
Males, n(%) 76 (42.2%) 104 (57.8%) - 
*p < 0.05, **includes Stroke/CVA, Other Neurological/Congenital Disease and Multiple 
Sclerosis 
 
3.2 NULL HYPOTHESIS 2 
Current primary MAEs were not equally distributed between the two groups; thus, the 
null hypothesis is rejected. In terms of power mobility devices, the data shows that when an ATP 
is involved, the PwD is likely to receive a group 3 power wheelchair. If there is no ATP, a group 
2 power wheelchair is likely to be provided. This is due to Medicare’s policy that in order to 
receive a group 3 power wheelchair, the beneficiary must be evaluated by an ATP (Centers for 
Medicare & Medicaid Services, 2017). Group 3 power wheelchairs are intended for individuals 
who have a diagnosis related to a neuro-muscular or congenital anomaly condition, mobility 
limitations that require a seating system with more than one seat function (ex. tilt, recline, and 
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elevating leg rests), sufficient for “all day” use, and are more durable (compared to group 1 and 2 
power wheelchairs) (Dicianno & Tovey, 2007). Unfortunately, for individuals who do not have 
an ATP but qualify for a group 3 power wheelchair, they are unlikely to receive one.  
In terms of manual wheelchairs, ATP’s are most likely to provide an ultra-lightweight 
wheelchair compared to another wheelchair (standard, lightweight, bariatric or transport) if there 
is no ATP involved. Ultra-lightweight wheelchairs weigh the least of all types of manual 
wheelchairs, weighing below thirty pounds. Lighter wheelchairs require less force to propel 
allowing the individual to push at faster speed at further distances while using less energy 
(Beekman, Miller-Porter, & Schoneberger, 1999). Ultra-lightweight wheelchairs are the only 
wheelchairs that are fully adjustable. Making correct adjustments and positioning can decrease 
rolling resistance and require less energy to propel (DiGiovine et al., 2012).  When comparing 
fatigue life using ANSI/RESNA’s durability tests, ultra-lightweights had the longest lifespan 
compared to other types of manual wheelchairs (Fitzgerald et al., 2001).  
A post hoc analysis was conducted to confirm if MAE was unevenly distributed between 
the two groups. The post hoc analysis was based on the most prevalent MAE and three of the 
most prevalent and similar diagnoses (stroke, other neurological/congenital disease and multiple 
sclerosis) between groups. The results show that MAE is unevenly distributed based on diagnosis 
between both groups X2(8)=41.85, p=0.000 (See Table 4) with PwD with an ATP are likely to 
receive a Group 3 Power Wheelchair and PwD without an ATP likely to receive an Other 
Wheelchair. 
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Table 4 MAE Comparison Based on Most Prevalent and Common Diagnoses** 
 
 ATP  
 Yes No X2 
Cane, Crutches, Walker, 
n(%) 
19 (10.9) 55 (23) 149.53* 
Other Wheelchairs, n(%) 24 (13.7) 128 (53.6) - 
Ultra-Lightweight Manual 
WC, n%) 
13 (7.4) 4 (1.7) - 
Group 2 Power WC, n(%)         43 (24.6) 47 (19.7) - 
Group 3 Power WC, n(%) 76 (43.4) 5 (2.1) - 
*p < 0.05, ** includes Stroke/CVA, Other Neurological/Congenital Disease and Multiple 
 
 Sclerosis 
 
3.3 NULL HYPOTHESIS 3 
There was a statistically significant difference in FMA scores when comparing the two 
groups; thus, the null hypothesis is rejected. On average, people who have an ATP are more 
satisfied with their MAE. This result can be attributed to an ATP’s ability to select the 
appropriate MAE. The selection of AT is crucial because the individual is expected to use the 
MAE for at least five years. The ATP is also expected to anticipate future needs of the individual 
and prepare intervention strategies in case of changes in the individual’s medical condition. 
Education regarding maintenance, safety and replacement of the MAE should also be given by 
the ATP. Proper training on how to use the MAE should also be a focal point to maximize the 
benefits and prevent secondary injuries.  
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3.4 STUDY LIMITATIONS 
Several limitations can be found in this study. The data for the variable “Age of MAE” 
was analyzed as continuous data but was collected as ordinal data. The mean average age of 
MAE for the group without an ATP (M=4.29) could have been impacted because of the 
population size in the “1 year or less” category (n=129). The population size within the “10 years 
or more” category was relatively small (n=31) and would not have had a major affect on the 
average age of MAE. For the ATP involvement group, the population within the “1 year or less” 
(n=22) and “10 years or more” (n=26) were relatively small and would not have a major impact 
on the average age of MAE. For this study, the age of MAE was used to predict the average 
amount of years an individual has been using their MAE. Although this should be accurate for 
the ATP involvement group because theses individuals are expected to be the first owners of 
their MAE, a significant difference may be found in the group without an ATP. This is due to the 
phrasing of the question. Instead, or in addition to asking for the age of the MAE, the person 
should be asked how many years they have been using their current MAE. Individuals without an 
ATP could have not been the original owner of the MAE currently being used, so the actual age 
of the MAE is being documented instead of the amount time they have been using the MAE.    
Another limitation can be associated with the FMA score. Like the variable “age of 
MAE,” the FMA is ordinal data that is being analyzed as continuous data. Ordinal data being 
analyzed as continuous data can report accurate results if the following assumptions can be 
made: sufficiently large number of response categories, absence of skewness and equal 
thresholds across items (Lubke & Bengt, 2004). For the purpose of this study, these assumptions 
26 
 
were made. However, the numerical distance between categories in the FMA can change 
depending if all questions were answered but was not taken into consideration for this study.  
3.5 FUTURE WORK 
Data should continuously be collected to gather information regarding both groups being 
investigated in this study. How long the current MAE has been used by its current owner should 
be included in future databases. Knowing how long the MAE has been used for before seeking 
replacement will give a more accurate representation of what types of MAE are being abandoned 
prematurely based on funding policy of replacing MAE when it reaches a 5-year lifecycle. If 
possible, data being collected should try to be measured on a continuous scale. Continuous data 
allows for flexibility and more common statistical testing, allowing the reader to interpret and 
comprehend the data easier. All data should be reviewed before submission to the database. 
Large amounts of cases were excluded from this study based on missing or erroneous data.  
This study provides an overview of the impact of ATP involvement in the provision of 
MAE. Many in-depth studies can be performed to further investigate the differences between 
these two groups. Current primary MAEs and diagnoses can be compared based on ATP 
involvement or not to further investigate what MAE is being provided to people with a specific 
diagnosis. This would show the difference in the types of MAE an ATP would provide compared 
to what an individual would receive without an ATP. These results could provide further 
evidence that if an ATP is an is involved, PwD are more likely to have MAE provided that meets 
their needs. 
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Future work should also include increasing awareness of an ATP to other medical 
professionals. If more medical professionals were aware of the benefits of having an ATP, more 
people with disabilities could be referred to one to receive more appropriate MAE to meet their 
needs. Increasing awareness of an ATP should be focused on the general public as well. With the 
growing number of people with disabilities becoming aware of an ATP, more ATP’s will be 
needed in order to meet the future demand.    
Future statistical testing that analyze FMA scores as continuous data should take into 
consideration report outcomes with “does not apply” chosen as one of the responses. This will 
change the total score, 60, and the numeric distance between each category will change. This will 
violate one of the assumptions made when analyzing ordinal data as continuous data. 
3.6 CONCLUSION 
ATP’s are recognized as having the ability to identify needs, select appropriate AT, and 
provide proper education and training for people with disabilities. This study provides evidence 
that there is a significant difference between people who receive MAE through an ATP and those 
who do not. This study also shows that there is still a large population of people with disabilities 
who do not have an ATP that require a MAE. Having an ATP results in receiving higher quality 
MAE, keeping the MAE longer, and higher FMA scores.     
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APPENDIX A 
RESNA STANDARDS OF PRACTICE FOR ASSISTIVE TECHNOLOGY 
PROFESSIONAL 
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